

IN THE SPECIFICATION

Please amend the specification as follows:

At page 86, after the sentence which ends "... based on the results of the virus entry assay and additional relevant laboratory test results and clinical information" and before the word "References," please insert the following tables:

TABLE 1

CELLS

Cell	Receptor
5.25	CXCR4, CD4, CCR5 (not expressed well) BONZO
5.25.Luc4.M7	CD4, CCR5, BONZO
HOS.CD4.CCR5	CD4, CCR5
HOS.CD4.CXCR4	CD4, CXCR4
HOS.CD4	CD4, low level expression of CCR5 and CXCR4
HOS HT4 R5 GFP wt	CD4, CXCR4, CCR5
HOS. CD4.CCR5.GFP.M7#6*	CD4, CXCR4, CCR5
P4.CCR5	CD4, CXCR4, CCR5
U87.CD4	CD4
U87.CD4 R5	CD4, CCR5
U87.CD4 X4	CD4, CXCR4
MT2	CD4, CXCR4
MT4	CD4, CXCR4
PM1	CD4, CXCR4, CCR5
CEM NKr CCR5	CD4, CXCR4, CCR5

Table 2**Representative viruses and reagents**

Viruses	Envelope ^a	Source
89.6, SF2	R5-X4/SI/B	ARRRP ^b
92BR014, 92US076	R5-X4/SI/B	ARRRP
JR-CSF, 91US005	R5/NSI/B	ARRRP
91US054	SI/B	ARRRP
NL43, MN, ELI	X4/B	ARRRP
92HT599	X4	ARRRP
92UG031	R5/NSI/A	ARRRP (IN-HOUSE)
92TH014, 92TH026	R5/NSI/B	ARRRP (IN-HOUSE)
92BR025, 93MW959	R5/SI/C	ARRRP (IN-HOUSE)
92UG035	R5/NSI/D	ARRRP (IN-HOUSE)
92TH022, 92TH023	R5/NSI/E	ARRRP (IN-HOUSE)
93BR020	R5-X4/SI/F	ARRRP (IN-HOUSE)
Antibodies	Epitope	SOURCE
Mabs 2F5, 1577	gp41 TM	ARRRP
Mabs IG1b12, 2G12, 17b, 48D	gp120 SU	ARRRP
Neutralization sera #2, HIV-IG	Polyclonal	ARRRP
Entry inhibitors	Target	Source
CD4-IG	gp120 SU	Genentech
CD4-IGG2	gp120 SU	Adarc
SCD4	Sigma	Progenics
T20 (DP178)	gp41 TM	Trimeris
Rantes, MIPIa/b	CCR5	SIGMA/ARRRP
SDF1a/b	CXCR4	SIGMA/ARRRP
AMD 3100	CXCR4	AnorMed
Dextran sulfate, Heparin	Non-specific	Sigma

^aR5 (CCR5 co-receptor), X4 (CXCR4 co-receptor)

SI (syncytium inducing), NSI (non-syncytium inducing), A,B,C,D,E,F (envelope clade designation)

^bAIDS Research and Reference Reagent Program

Table 3

Primers Tested for the Amplification of HIV Envelope	
RT PRIMERS	
RT Primer 1	5'-GGA GCA TTT ACA AGC AGC AAC ACA GC-3'
RT Primer 2	5'-TTC CAG TCA VAC CTC AGG TAC-3'
RT Primer 3	5'-AGA CCA ATG ACT TAY AAG G-3'
5' PCR PRIMERS	
5' env Primer 1	5'-GGG CTC GAG ACC GGT CAG TGG CAA TGA GAG TGA AG-3'
5' env Primer 2	5'-GGG CTC GAG ACC GGT GAG CAG AAG ACA GTG GCA ATG A-3'
5' env Primer 3	5'-GGG CTC GAG ACC GGT GAG CAG AAG ACA GTG GCA ATG -3'
3' PCR PRIMERS	
3' env Primer 1	5'-GGG TCT AGA ACG CGT TGC CAC CCA TCT TAT AGC AA- 3'
3' env Primer 2	5'-GGG TCT AGA ACG CGT CCA CTT GCC ACC CAT BTT ATA GC-3'
3' env Primer 3	5'-GGG TCT AGA ACG CGT CCA CTT GCC ACC CAT BTT A-3'
3' env Primer 4	5'-GAT GGT CTA AGA CGC TGT TCA ATA TCC CTG CCT AAC TC-3'

Table 4 (Panel 1)**Anti-HIV Drugs**

Drug/Compound	Generic Name	Trademark	Manufacturer
RT Inhibitors (NRTI, nucleotide analogs)			
AZT, ZDV	Zidovudine	Retrovir	Glaxo/Wellcome
3TC	Lamivudine	Epivir	Glaxo/Wellcome
AZT + 3TC		Combivir	Glaxo/Wellcome
d4T	Stavudine	Zerit	Bristol-Myers/Squibb
ddl	Didanosine	Videx	Bristol-Myers/Squibb
ddC	Zalcitabine	Hivid	Hoffman La Roche
1592U89	Abacavir	Ziagen	Glaxo/Wellcome
AZT + 3TC + 1592U89		Trizivir	Glaxo/Wellcome
(-)FTC (5-fluoro-3TC; Corviracil)	Emtricitabine		Triangle Pharmaceuticals
(-)FTC + (+)FTC (50:50)	Racimir		QuadPharma
DAPD (DXG active)	Amdoxovir		Triangle Pharmaceuticals
F-ddA (2-fluoro-ddA)	Lodenoine		MedImmune Oncology (US Bioscience)
BCH-10652, dOTC (2-deoxy-3-oxa-4-thiocytidine)			BioChem Pharma, Inc.
D-d4FC			Triangle Pharmaceuticals (Schinazi)
RT Inhibitors (NTRTI, nucleotide analogs)			
bis-POC PMPA (GS-4331)	Tenofovir		Gilead Sciences
bis-POM PMEA (GS-840)	Adefovir dipivoxil		Gilead Sciences
RT Inhibitors (NNRTI, non-nucleosides)			
BI-RG-587	Nevirapine	Viramune	Boehringer/Ingelheim (Roxanne)
BHAP PNU-90152T	Delavirdine	Rescriptor	Pharmacie & Upjohn
DMP 266 (L-743,726)	Efavirenz	Sustiva	Dupont Pharmaceuticals (Avid)
MKC442	Emivirine		Triangle/Mitsubishi Kasei
AG-1549 (S1153) (on hold)	Capravirine		Agouron Pharmaceuticals
PNU-142721			Pharmacia & Upjohn
DPC-961, -963, -083, -08?			DuPont Pharmaceuticals
SJ-3366	Also entry inhibitor?		Samjin Pharmaceuticals
BHAP PNU-87201	Ateviridine		Upjohn
GW420867X (quinoxaline)	(2nd gen. HBY 097)		Glaxo/Wellcome (Hoechst Bayer)
TMC 120 (R147681)			Tibotec
TMC 125 (R165335)			Tibotec
R86183	tivirapine		Janssen Pharmaceuticals
Calanolide A			Sarawak Medichem Pharmaceuticals
Protease Inhibitors (PRI)			
Ro 31-8959	Saquinavir-(hgc) Saquinavir-(sgc)	Invirase Fortivase	Hoffman-La Roche
MK-639 (L-735,524)	Indinavir	Crixivan	Merck Research Laboratories

ABT-538 (A-84538)	Ritonavir	Norvir	Abbott Laboratories
AG1343	Nelfinavir	Viracept	Agouron Pharmaceuticals
141W94 (VX-478)	Amprenavir	Agenerase	Glaxo-Wellcome/Vertex
ABT-378/r	Lopinavir/ritonavir	Kaletra	Abbott Laboratories
BMS 232,632 (aza-peptide)			Bristol-Myers-Squibb
PNU-140690	Tipranavir		Pharmacia & Upjohn
DMP 450 (cyclic urea)	Mozenavir		Triangle/Avid (ph I/II)
TMC 126 (Erickson's compound)			Tibotec
G/W433908 (VX-175)	amprenavir pro-drug		Glaxo/Wellcome/Vertex
L756,423 (on hold)			Merck
PD-178390 (dihydropyrone)			Parke Davis (Boehringer-Ingelheim)
? new candidate			Roche
DPC 681 and 684			DuPont Pharmaceuticals
AG-1776 (JE-2147 = KNI-764)			Agouron Pharmaceuticals
Envelope/Receptor Inhibitors			
T-20 (gp41)	Pentafuside		Trimeris Pharmaceuticals
T-1249 (gp41)			Trimeris Pharmaceuticals
D-peptide inhibitor (gp41) small mol.	SCH-C		Schering-Plough
AMD-3100 (CXCR4)	(bicyclam)		AnorMED
AMD-3664 (CXCR4)	(macrocyclam)		AnorMED
ALX40-4C (CXCR4)			U. PA
FP21399			Fuji Pharmaceuticals
PRO 542 (gp120)	CD4lgG2		Progenics Pharmaceuticals
PRO-140 (CCR5)	MAb CCR5		Progenics Pharmaceuticals
T-22 (CXCR4)	(peptide, 18-mer)		
Met-SDF-1 (CXCR4)			
TAK 779 (CCR5 antagonist)			Takeda
AOP-Rantes (CCR5)			Gryphon Sciences

Table 4 (Panel 2)

Rantes 9-68 (CCR5)			
CCR5 antagonists	4-(piperidin-1-yl) butane class		Merck
α -Immunokine-NNS03 (CCR5, CXCR4)	α -cobratoxin		PhyloMed Corp.
Integrase Inhibitors			
AR-177	Zintevir		Aronex Pharmaceuticals
Diketo acids			Merck Research Laboratories
Nucleocapsid Inhibitors			
RB 2121	cyclic peptide p7 mimic		(see PNAS 96:4886-4891 (1999))
CI-1012			Achelion Pharmaceuticals
Rnase H Inhibitor			
SP1093V (BBNH Fe+3 derivative)			(Parniak)

Table 4 (Panel 3)

Generic Name (abbreviation)	Brand Name	Firm	FDA Approval Date
zidovudine, AZT	Retrovir	Glaxo Wellcome	March 87
didanosine, ddl	Videx	Bristol Myers-Squibb	October 91
zalcitabine, ddC	Hivid	Hoffman-La Roche	June 92
stavudine, d4T	Zerit	Bristol Myers-Squibb	June 94
lamivudine, 3TC	Epivir	Glaxo Wellcome	November 95
saquinavir, SQV, hgc	Invirase	Hoffman-La Roche	December 95
saquinavir, SQV, sgc	Fortovase	Hoffman-La Roche	November 97
ritonavir, RTV	Norvir	Abbott Laboratories	March 96
indinavir, IDV	Crixivan	Merck & Co., Inc.	March 96
nevirapine, NVP	Viramune	Boehringer Ingelheim	June 96
nelfinavir, NFV	Viracept	Agouron Pharmaceuticals	March 97
delavirdine, DLV	Rescriptor	Pharmacia & Upjohn	April 97
ZDV+3TC	Combivir	Glaxo Wellcome	September 97
efavirenz, EFV	Sustiva	DuPont Pharmaceuticals	September 98
abacavir, ABC	Ziagen	Glaxo Wellcome	February 99
amprenavir	Agenerase	Glaxo Wellcome	April 99
lopinavir/ritonavir	Kaletra	Abbott	September 2000
ZDV+3TC+ABC	Trizivir	GlaxoSmithKline	November 2000